Peoples Financial Services CORP. lessened its position in Eli Lilly And Co (NYSE:LLY) by 2.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 16,475 shares of the company’s stock after selling 350 shares during the quarter. Eli Lilly And Co makes up about 1.1% of Peoples Financial Services CORP.’s portfolio, making the stock its 27th biggest position. Peoples Financial Services CORP.’s holdings in Eli Lilly And Co were worth $1,907,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in LLY. Cozad Asset Management Inc. grew its stake in Eli Lilly And Co by 6.8% in the fourth quarter. Cozad Asset Management Inc. now owns 2,493 shares of the company’s stock valued at $288,000 after purchasing an additional 159 shares in the last quarter. Waverton Investment Management Ltd boosted its stake in shares of Eli Lilly And Co by 1.9% during the 4th quarter. Waverton Investment Management Ltd now owns 12,724 shares of the company’s stock worth $1,472,000 after acquiring an additional 238 shares during the period. HT Partners LLC boosted its stake in shares of Eli Lilly And Co by 15.9% during the 4th quarter. HT Partners LLC now owns 4,367 shares of the company’s stock worth $505,000 after acquiring an additional 600 shares during the period. Kessler Investment Group LLC boosted its stake in shares of Eli Lilly And Co by 236.3% during the 4th quarter. Kessler Investment Group LLC now owns 33,876 shares of the company’s stock worth $3,920,000 after acquiring an additional 23,804 shares during the period. Finally, Carroll Financial Associates Inc. boosted its stake in shares of Eli Lilly And Co by 1.3% during the 4th quarter. Carroll Financial Associates Inc. now owns 7,029 shares of the company’s stock worth $810,000 after acquiring an additional 91 shares during the period. 77.02% of the stock is currently owned by institutional investors and hedge funds.
In other Eli Lilly And Co news, SVP Myles O’neill sold 25,000 shares of the company’s stock in a transaction dated Monday, December 10th. The stock was sold at an average price of $112.92, for a total value of $2,823,000.00. Following the completion of the transaction, the senior vice president now owns 26,562 shares of the company’s stock, valued at approximately $2,999,381.04. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 15,500 shares of the company’s stock in a transaction dated Tuesday, December 4th. The stock was sold at an average price of $119.00, for a total value of $1,844,500.00. Following the completion of the transaction, the insider now directly owns 118,015,304 shares of the company’s stock, valued at approximately $14,043,821,176. The disclosure for this sale can be found here. Insiders have sold a total of 1,702,736 shares of company stock valued at $124,427,811 in the last three months. 0.11% of the stock is owned by insiders.
Shares of Eli Lilly And Co stock traded down $1.74 during trading on Monday, reaching $114.44. 1,693,213 shares of the company’s stock were exchanged, compared to its average volume of 4,772,150. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.53 and a current ratio of 1.91. Eli Lilly And Co has a 1-year low of $73.69 and a 1-year high of $119.84. The stock has a market capitalization of $124.16 billion, a P/E ratio of 26.74, a price-to-earnings-growth ratio of 1.68 and a beta of 0.33.
Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Tuesday, November 6th. The company reported $1.39 EPS for the quarter, topping analysts’ consensus estimates of $1.35 by $0.04. Eli Lilly And Co had a return on equity of 42.84% and a net margin of 1.85%. The company had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. During the same quarter in the previous year, the firm earned $1.05 EPS. Eli Lilly And Co’s revenue was up 7.1% on a year-over-year basis. On average, research analysts forecast that Eli Lilly And Co will post 5.59 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Friday, February 15th will be issued a dividend of $0.645 per share. The ex-dividend date is Thursday, February 14th. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.25%. This is a boost from Eli Lilly And Co’s previous quarterly dividend of $0.56. Eli Lilly And Co’s payout ratio is 52.57%.
LLY has been the subject of several research analyst reports. TheStreet upgraded Eli Lilly And Co from a “c+” rating to a “b+” rating in a research note on Tuesday, November 6th. Cantor Fitzgerald set a $110.00 price target on Eli Lilly And Co and gave the company a “buy” rating in a research note on Monday, September 17th. Zacks Investment Research upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $129.00 price target for the company in a research note on Tuesday, October 9th. Guggenheim started coverage on Eli Lilly And Co in a research note on Monday, October 8th. They issued a “buy” rating for the company. Finally, ValuEngine upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating in a research note on Monday, October 8th. Ten investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $111.50.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Zolmax and is owned by of Zolmax. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://zolmax.com/investing/peoples-financial-services-corp-sells-350-shares-of-eli-lilly-and-co-lly/2824362.html.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Read More: Investing in Growth Stocks
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.